Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | CTSL | P07711 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376172 | 1.00 | PDE4B (0.56) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL28542087 | 1.00 | PDE4B (0.56) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL28840263 | 1.00 | PDE4B (0.56) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL13315211 | 0.92 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL19918950 | 0.92 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL3388396 | 0.92 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL1355893 | 0.92 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL3388401 | 0.92 | PDE4B (0.54) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL30060223 | 0.91 | PDE4B (0.59) | PDE4BSMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL7498881 | 0.91 | PDE4B (0.59) | PDE4BSMN1; SMN2NPC1RAB9AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289801-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-09-18 | — | — | US | disclosed |
| CN-115135642-B | Inhibitors of EGFR mutant forms | 缆图药品公司 | 2025-03-04 | — | — | CN | disclosed |
| US-12172983-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2024-12-24 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718602-B2 | EGFR inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2023-08-08 | — | — | US | disclosed |
| US-20230056541-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-02-23 | — | — | US | disclosed |
| US-20230026209-A1 | EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-01-26 | — | — | US | disclosed |
| EP-4081515-A1 | INHIBITORS OF MUTANT FORMS OF EGFR | Blueprint Medicines Corporation (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115135642-A | Inhibitors of mutant forms of EGFR | 缆图药品公司 | 2022-09-30 | — | — | CN | disclosed |
| US-9963448-B2 | Bicyclic inhibitors of PAD4 | PADLOCK THERAPEUTICS, INC. (US) | 2018-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230056541-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | PDE4B 3788/4885SMN1; SMN2 4618/4885NPC1 1359/4885 |
| US-20230026209-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | PDE4B 3788/4885SMN1; SMN2 4618/4885NPC1 1359/4885 |
| US-11718602-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | PDE4B 3788/4885SMN1; SMN2 4618/4885NPC1 1359/4885 |
| US-12172983-B2 | EGFR inhibitors | EGFR, ERBB2, ERBB3 | PDE4B 3788/4885SMN1; SMN2 4618/4885NPC1 1359/4885 |
| US-20250289801-A1 | EGFR INHIBITORS | EGFR, ERBB2, ERBB3 | PDE4B 3788/4885SMN1; SMN2 4618/4885NPC1 1359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.